Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
C. R. Bard
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
6 months post primary RYGB with inadequate weight loss or weight regain
BMI \>30 and ≤ 50
Dilated gastrojejunal anastomosis
Successfully completes screening process
Signed consent
You may not be if
Recently quit smoking or plan to quit within the next year
Pregnant or planning to become pregnant over the course of the next 9 months
Mallampati score of 4
Serious systemic disease or active disease of the gastrointestinal tract
Gastric pouch abnormalities
Significant movement limitations
Use of weight-promoting or weight-reduction drugs during study period
Severe eating disorders
Uncontrolled depression or psychoses
Ongoing severe complication resulting from initial RYGB or other condition that in the investigators' assessment would make the patient an unsuitable candidate for the study procedure
History of significant cardiovascular, cerebrovascular or pulmonary disease
Not a candidate for conscious or general sedation
Anticoagulant therapies
Active substance abuse
Life expectancy \< 1 year
Enrolled in another investigational drug or device trial that has not completed the primary endpoint or that clinically interferes with this trial's study endpoints
Clareo Health | Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass
